What Most People Get Wrong About GLP-1 Drugs Like Ozempic, Wegovy and Zepbound

“When it comes to the economics of medications, it’s really hard to point your finger at a rational cause,” Pruitt said. “The manufacturing processes aren’t necessarily disclosed, so you can’t look at that as a contributing factor in a meaningful way. I think oftentimes what we see in the United States, it’s really what the market can bear.”

“They’re expensive and they’re in high demand. And so that’s a bad combination,” said Paul Pruitt, the co-founder of SHARx, a company that helps people get their hands on expensive medicines.